<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01504906</url>
  </required_header>
  <id_info>
    <org_study_id>D5130C00074</org_study_id>
    <nct_id>NCT01504906</nct_id>
  </id_info>
  <brief_title>Study to Assess Effect of Cyclosporine on the Blood Levels of Ticagrelor</brief_title>
  <official_title>A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, and Tolerability of Cyclosporine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AstraZeneca</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the effect of Cyclosporine on the blood levels of
      Ticagrelor.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A Single-Center,Open-Label,Randomized,3-Treatment,3-Period Cross-Over Study to Investigate
      the Potential Effect of Cyclosporine on the Pharmacokinetics, Safety, and Tolerability of
      Ticagrelor and the Effect of Ticagrelor on the Pharmacokinetics, Safety, and Tolerability of
      Cyclosporine.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>January 2012</start_date>
  <completion_date type="Actual">June 2012</completion_date>
  <primary_completion_date type="Actual">June 2012</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Description of the pharmacokinetic (PK) profile for Ticagrelor and its metabolite AR-C124910XX in terms of maximum concentration (Cmax),time to maximum concentration (tmax) and area under the concentration curve from time zero to infinity (AUC)</measure>
    <time_frame>PK samples will be collected postdose 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, and 48 hours</time_frame>
    <description>PK samples will be collected postdose at visits 2,3 and 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the PK profile for Ticagrelor and its metabolite AR-C124910XX in terms of area under the concentration-time curve from time zero to the last measurable concentration (AUC(0-t)),terminal half-life (t1/2)</measure>
    <time_frame>PK samples will be collected postdose 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, and 48 hours</time_frame>
    <description>PK samples will be collected postdose at visit 2,3 and 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the PK profile for AR-C124910XX : ticagrelor in terms of ratios for Cmax, AUC(0-t), and AUC</measure>
    <time_frame>PK samples will be collected postdose 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, and 48 hours</time_frame>
    <description>PK samples will be collected postdose at visit 2,3 and 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Description of the PK profile for Cyclosporine in terms of Cmax, AUC(0-t), AUC, tmax and t1/2</measure>
    <time_frame>PK samples will be collected postdose 0.5, 1, 2, 3, 4, 6, 8, 12, 18, 24, 36, and 48 hours</time_frame>
    <description>PK samples will be collected postdose at visit 2,3 and 4</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Description of the safety profile in terms of adverse events, blood pressure, pulse, temperature, ECG (Electrocardiogram), physical examination, and safety laboratory variables</measure>
    <time_frame>Baseline up to 45 days</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">20</enrollment>
  <condition>Healthy</condition>
  <arm_group>
    <arm_group_label>A</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>cyclosporine 600 mg+ a single oral dose of 180 mg ticagrelor</description>
  </arm_group>
  <arm_group>
    <arm_group_label>B</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose cyclosporine 600 mg</description>
  </arm_group>
  <arm_group>
    <arm_group_label>C</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>single dose 180 mg ticagrelor</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclosporine</intervention_name>
    <description>Oral tablets, 600 mg , single dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>B</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>ticagrelor</intervention_name>
    <description>Oral tablets, 180 mg, single dose</description>
    <arm_group_label>A</arm_group_label>
    <arm_group_label>C</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Provision of signed and dated written informed consent prior to any study-specific
             procedures

          -  Healthy male subjects aged 18 to 45 years (inclusive) with suitable veins for
             cannulation or repeated venipuncture

        Exclusion Criteria:

          -  History or presence of gastrointestinal, hepatic or renal disease, or any other
             condition known to interfere with absorption, distribution, metabolism, or excretion
             of drugs

          -  A history of hemophilia, von Willebrand's disease, lupus anti-coagulant, or other
             diseases/syndromes that can either alter or increase the propensity for bleeding

          -  A personal history of vascular abnormalities including aneurysms; a personal history
             of severe hemorrhage, hematemesis, melena, hemoptysis, severe epistaxis, severe
             thrombocytopenia, intracranial hemorrhage, or rectal bleeding within 1 year
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Miriana Kujacic, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Molndal, Sweden AstraZeneca</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Kelli Craven, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Overland Park US, Quintiles, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research site</name>
      <address>
        <city>Overland Park</city>
        <state>Kansas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 2, 2012</study_first_submitted>
  <study_first_submitted_qc>January 5, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 6, 2012</study_first_posted>
  <last_update_submitted>December 11, 2012</last_update_submitted>
  <last_update_submitted_qc>December 11, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 12, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Healthy male volunteers</keyword>
  <keyword>pharmacokinetics</keyword>
  <keyword>cyclosporine</keyword>
  <keyword>ticagrelor</keyword>
  <keyword>Bioavailability (plasma AUC, Cmax, plasma AUC0-t, t1/2Î»z, tmax)</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclosporins</mesh_term>
    <mesh_term>Cyclosporine</mesh_term>
    <mesh_term>Ticagrelor</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

